跳至主要内容
临床试验/CTRI/2024/01/062052
CTRI/2024/01/062052尚未招募2/3 期

Anti-hypertensive and pleiotropic effects of Moringa oleifera leaf extract as an add-on therapy in patients with essential hypertension - A randomized double blind placebo controlled trial.

JIPMER Puducherry1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2024年2月1日最近更新:
适应症
相关药物

试验速览

阶段
2/3 期
状态
尚未招募
入组人数
150
试验地点
1
主要终点
Mean change from baseline in systolic blood pressure at the end of 3 months

研究概览

简要总结

This study is a randomized double blind placebo controlled trial to evaluate the effect of Moringa oleifera leaf extract as an add on treatment in patients with essential hypertension.  The study will have two arms- the intervention arm and the placebo arm.  The study will be conducted with 150 participants, 75 in each group, all of whom will be recruited from JIPMER, Puducherry.  The participants will receive either the intervention or placebo capsules at a dose of 600 mg thrice daily for a period of three months.  At the end of three months, the participants will be assessed for mean reduction in systolic blood pressure, mean reduction in diastolic blood pressure, oxidative stress marker and antioxidant level, HbA1c level, liver and renal function test, lipid profile, hs-CRP, serum uric acid level and endothelial function using plethysmography and will be compared to baseline.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 75.00 Year(s)(—)
性别
All

入选标准

  • Patients with essential hypertension aged ≥ 18 years, irrespective of gender, with or without other comorbidities, who fulfill the following criteria: Patients on treatment with stable dose of antihypertensive agents for atleast 1 month and has not yet attained target blood pressure goals (130 mm Hg of systolic and 80 mm Hg of diastolic blood pressure) and not requiring dose escalation or addition of new anti-hypertensive agent according to clinical judgment of the treating physician.

排除标准

  • Patients with secondary hypertension.
  • Patients with hypertensive urgency or emergency.
  • Patients not on stable dose of oral hypoglycemic drugs or insulin for past 1 month.
  • Pregnant and lactating women, women in reproductive age group not practicing contraceptive measures.
  • Patients with hepatic impairment (elevated liver enzymes more than 2 times upper normal limit) Patients with renal impairment (serum Creatinine more than 1.2 mg per dl) Patients with recent history of coronary artery disease Patients with peripheral vascular disease.
  • Patients who had participated in other trials in the past three months.

结局指标

主要结局

Mean change from baseline in systolic blood pressure at the end of 3 months

时间窗: 3 months

次要结局

  • Mean change from baseline in diastolic blood pressure, HbA1c level, oxidative stress marker and antioxidant level, hs-CRP, liver and renal function, lipid profile, serum uric acid level and endothelial function using plethysmography at the end of 3 months(3 months)
  • Safety of Moringa oleifera leaf extract in essential hypertension patients(3 months)

研究者

申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Harivenkatesh Natarajan

Jawaharlal Institute of Postgraduate Medical Education & Research

研究点 (1)

Loading locations...

相似试验